InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Browse the complete record of transactions filed by Bruno Lafont, Chairman & CEO. Officer active across 1 companies, notably NFL Biosciences. In total, 7 filings have been recorded. Total volume traded: €337k. The latest transaction was disclosed on 2 September 2025 (Cession). Regulator: AMF. All data is accessible without signup.
Declarations7 total
€27,40518,000 shares@ €1.52250.14% mcap5.9% of flow
ActionEuronext Growth Paris
2025DD1056681·
€49,48941,650 shares@ €1.18820.26% mcap10.7% of flow
ActionEuronext Growth Paris
2025DD1049758·
€75,000250,000 shares@ €0.300.39% mcap16.2% of flow
ActionEuronext Growth Paris
2025DD1032010·
€50,000500,000 shares@ €0.100.26% mcap10.8% of flow
ActionEuronext Growth Paris
2023DD918253·
€151,27257,000 shares@ €2.65390.78% mcap32.8% of flow
ActionEuronext Growth Paris
2023DD918168·
€108,51543,000 shares@ €2.52360.56% mcap23.5% of flow
ActionEuronext Growth Paris
2023DD918207·
071,778 shares0
ActionEuronext Growth Paris
2023DD897035·
7 of 7 declarations
About Bruno Lafont
Bruno Lafont is a well-known figure in French corporate governance and is currently best identified as Chairman and Chief Executive Officer of NFL Biosciences, which he co-founded. In this role, he leads the company’s strategy, organizational structuring, and project development. NFL Biosciences describes him as a co-founder who has been deeply involved in the company since 2009, with responsibility for its technical and operational development. Recent company disclosures continue to show him at the center of the group’s governance and decision-making. Before joining NFL Biosciences, Lafont built most of his career in industrial and international leadership roles. He spent 12 years at PCM, where he served first as Innovation Director and later as President, including overseeing the setup of the group’s U.S. subsidiary in Houston, Texas. That experience gave him strong expertise in innovation management, cross-border expansion, and leadership in multicultural environments. His professional reputation was shaped even more broadly by his long tenure at Lafarge, where he held senior executive positions and ultimately became Chief Executive Officer and Chairman. He led the company through a period of major international expansion and was involved in key strategic decisions affecting its global footprint and its relationship with Holcim. This made him one of the prominent French executives associated with large listed industrial groups, with recognized experience in corporate governance, operational oversight, risk management, and large-scale transformation. At NFL Biosciences, Lafont represents the profile of an entrepreneur-executive combining strategic vision, financial discipline, and an understanding of the regulatory and scientific constraints of the life sciences sector. His responsibilities include supporting the company’s clinical programs, helping structure its financing and capital markets strategy, and guiding its long-term development. His background in international industry and listed-company governance is a valuable asset for a company pursuing innovation-driven growth.
